Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience.

被引：0
|
作者：
O'Connor, Owen A.
Hamlin, P. A.
Gerecitano, J.
Portlock, C. S.
Noy, A.
Moskowitz, C.
Straus, D. J.
Sarasohn, D.
Dumetrescu, O.
Pappanicolou, J.
Neylon, E.
Zelenetz, A. D.
Saunders, M. E.
Mould, D. R.
Fleischer, M.
Sirotnak, F.
Horwitz, S. M.
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Allos Therapeut Inc, Westminster, CO USA
[3] Project Res, Phoenix, AZ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
400
引用
收藏
页码：122A / 123A
页数：2
相关论文
共 50 条
  • [1] Pralatrexate (PDX) produces a high and durable complete response rate in patients with chemotherapy resistant T-cell lymphomas
    O'Connor, O. A.
    Hamlin, P.
    Moskowitz, C.
    Portlock, C.
    Sarasohn, D.
    Dumitrescu, O.
    Neylon, E.
    Patterson, M.
    Zelenetz, A.
    Saunders, M.
    Cagnoni, P.
    Mould, D.
    Fleisher, M.
    Califano, A.
    Sirotnak, F.
    Horwitz, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [2] Phase I/II trial of pralatrexate in patients with chemotherapy-resistant precursor and peripheral T-cell lymphomas
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 338 - 339
  • [3] Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Maeda, Yoshinobu
    Nakane, Takahiko
    Shimoyama, Tatsu
    Nakazato, Tomonori
    Sakai, Rika
    Ishikawa, Takayuki
    Izutsu, Koji
    Ueda, Ryuzo
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (10): : 2061 - 2068
  • [4] Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity.
    O'Connor, O
    Hamlin, PA
    Neylon, E
    Moskowitz, C
    Portlock, CS
    Straus, DJ
    Noy, A
    Cortelli, B
    Zelenetz, AD
    Fleisher, M
    Sarasohn, DD
    Sirotnak, FMM
    Horwitz, S
    BLOOD, 2005, 106 (11) : 752A - 752A
  • [5] Clofarabine is active in peripheral T-cell lymphomas: Results of the phase I portion of a phase I/II study
    Horwitz, S.
    Mulford, D.
    Paul, H.
    Weissbrot, H.
    Zelenetz, A. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 157 - 157
  • [6] Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
    O'Connor, Owen A.
    Hamlin, Paul A.
    Portlock, Carol
    Moskowitz, Craig H.
    Noy, Ariela
    Straus, David J.
    MacGregor-Cortelli, Barbara
    Neylon, Ellen
    Sarasohn, Debra
    Dumetrescu, Otila
    Mould, Diane R.
    Fleischer, Martin
    Zelenetz, Andrew D.
    Sirotnak, Frank
    Horwitz, Steven
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) : 425 - 428
  • [7] Survival outcomes of patients with peripheral T-cell lymphomas (PTCL) treated with chemotherapy and/or novel agents: The Columbia University experience.
    Ma, Helen
    Cheng, Bin
    O'Connor, Owen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
    O'Connor, O.
    Pro, B.
    Pinter-Brown, L.
    Popplewell, L.
    Bartlett, N.
    Lechowicz, M.
    Savage, K.
    Coiffier, B.
    Saunders, M.
    Horwitz, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Results of the PROPEL Study: Phase II Trial of Pralatrexate plus Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02): : 129 - 130
  • [10] Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study
    Jong Gwang Kim
    Sang Kyun Sohn
    Yee Soo Chae
    Yoon Young Cho
    Deok Hwan Yang
    Je-Jung Lee
    Hyeoung-Joon Kim
    Ho Jin Shin
    Joo Seop Chung
    Goon Jae Cho
    Won-Sik Lee
    Young-Don Joo
    Chang-Hak Sohn
    Suk Joong Oh
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 129 - 134
12345